# US 2016/0250220 A1 · Treatment for pancreatic cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250220 A1
- Document ID: US20160250220A1
- Status: Published application
- Kind: A1
- Application number: 15/029,269
- Filed: 2014-10-03
- Published: 2016-09-01
- Earliest claimed: 2013-10-18
- Assignees: University Health Network
- Applicants: University Health Network
- Inventors: David W. Hedley; Ines Lohse; Jacqueline M. Mason; Mark R. Bray
- Web page: https://patentgrep.com/patent/US20160250220A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- C07D 403/08: linked by a carbon chain containing alicyclic rings
- C07D 413/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating a subject with pancreatic cancer, comprising administering an effective amount of a compound of structural formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
each Ra is independently —H or methyl;
R1 is —H, or methoxy; and
R2 is —H, or methyl.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pancreatic cancer is an exocrine tumor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pancreatic cancer is a neuroendocrine tumor.

### Claim 7 (depends on 5)

The method of claim 5, wherein the exocrine tumor is selected from the group consisting of acinar cell carcinoma, adenocarcinoma, adenosquamous carcinoma, giant cell tumor, intraductal papillary-mucinous neoplasm (IPMN), mucinous cystadenocarcinoma, pancreatoblastoma, serous cystadenocarcinoma, and solid and pseudopapillary tumors.

### Claim 8 (depends on 6)

The method of claim 6, wherein the neuroendocrine tumor is selected from the group consisting of gastrinoma (Zollinger-Ellison Syndrome), glucagonoma, insulinoma, nonfunctional islet cell tumor, somatostatinoma, and vasoactive intestinal peptide-releasing tumor (VIPoma or Verner-Morrison Syndrome).

### Claim 9 (depends on 1)

The method of claim 1, wherein the pancreatic cancer is adenocarcinoma.

### Claim 10 (depends on 1)

The method of claim 1, wherein the pancreatic cancer is hypoxic.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pancreatic cancer is non-hypoxic.

### Claim 12 (depends on 1)

The method of claim 1, further comprising co-administering an additional therapeutic agent.

### Claim 13 (depends on 12)

The method of claim 12, wherein the additional therapeutic agent is an anti-cancer drug.

### Claim 14 (depends on 13)

The method of claim 13, wherein the anti-cancer drug is Gemcitabine.

### Claim 15 (depends on 13)

The method of claim 13, wherein the anti-cancer drug is Cisplatin.
